VergleichsstudieSystematische Übersicht
125I versus 103Pd brachytherapy for low risk prostate cancer: a systematic review
Chinese Journal of Cancer · 2009
DOI: 10.5732/cjc.008.10378 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Chinese Journal of Cancer, 2009. Verfasst von Lin-Lin Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Evidence-based Medicine Center of Lanzhou University, School of Basic Medical Science, Lanzhou University, Lanzhou, Gansu, 73000, P.R.China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
BrachytherapyDatabases, BibliographicDisease-Free SurvivalHumansIodine RadioisotopesMalePalladiumProstatic NeoplasmsRadiation InjuriesRadioisotopesRandomized Controlled Trials as TopicRectal DiseasesUrologic Diseases
Substanzen
Iodine RadioisotopesRadioisotopesPalladium
Autor:innen und Institutionen
- Evidence-based Medicine Center of Lanzhou University, School of Basic Medical Science, Lanzhou University, Lanzhou, Gansu, 73000, P.R.China.
Zitieren
APA
Zhang, L. L., Ma, L., Tian, J. H., Ren, Y. Y., & Yang, K. H. (2009). 125I versus 103Pd brachytherapy for low risk prostate cancer: a systematic review. Chinese Journal of Cancer. https://doi.org/10.5732/cjc.008.10378
Vancouver
Zhang LL, Ma L, Tian JH, Ren YY, Yang KH. 125I versus 103Pd brachytherapy for low risk prostate cancer: a systematic review. Chinese Journal of Cancer. 2009. doi:10.5732/cjc.008.10378
BibTeX
@article{Zhang2009,
author = {Zhang, Lin-Lin and Ma, Li and Tian, Jin-Hui and Ren, Yao-Yao and Yang, Ke-Hu},
title = {125I versus 103Pd brachytherapy for low risk prostate cancer: a systematic review},
journal = {Chinese Journal of Cancer},
year = {2009},
doi = {10.5732/cjc.008.10378}
}
EUVIMED